Last updated: March 1, 2026
What is NDC 45802-0953?
NDC 45802-0953 corresponds to Sebelipase alfa, a recombinant enzyme indicated for the treatment of lipid storage disorders such as lysosomal acid lipase deficiency (LAL-D). Approved by FDA in 2015, it is marketed by Brighton Therapeutics.
Market Size and Demand Factors
Patient Population
LAL-D is an ultra-rare hereditary disease with an estimated prevalence of 1 in 300,000 to 1 in 400,000 live births globally. The total diagnosed population is believed to be fewer than 1,000 patients, with active treatment doses approximating 100-200 patients per year in major markets (US, EU, Japan).
Key Markets
- United States: The primary revenue driver, with an estimated 150 treated patients.
- European Union: Slightly smaller number, estimated at 70–100 patients.
- Japan: Limited data, but approximately 20–30 patients.
Competitive Landscape
Currently, Sebelipase alfa has no direct biosimilar competitors. It competes with supportive therapies and off-label management for related lipid disorders. The rarity and specificity of LAL-D limit market size.
Price Analysis and Projections
Current Pricing
The list price of Sebelipase alfa varies by market:
- United States: Approximate annual treatment cost per patient is $400,000 to $500,000.
- Europe and Japan: Prices range from €350,000 to €450,000, depending on local healthcare negotiations.
Pricing Components
The high cost reflects:
- Enzyme manufacturing complexity.
- Small patient populations and high development costs.
- Regulatory and distribution expenses.
Price Trends
- Over the past five years, pricing has remained stable due to lack of alternatives.
- Negotiations with payers, especially in Europe, have led to discounts ranging from 10% to 20% on list prices in some countries.
Future Price Projections
- Stable Pricing (2023–2027): List prices are unlikely to decline significantly owing to production costs and limited competition.
- Potential Increases: Based on inflation, manufacturing cost increases, or regulatory changes, prices could rise by 3–5% annually.
- Market Expansion Impact: New indications or broader approval could marginally increase demand, possibly allowing for higher prices or expanded access.
Revenue Projections
Assuming:
- 200 treated patients in major markets.
- US price at $450,000 per year.
- European and Japanese average price at $400,000.
Estimated annual revenue (2023):
| Market |
Patients |
Price per Patient |
Revenue |
| United States |
150 |
$450,000 |
$67.5 million |
| Europe |
70–100 |
€350,000–€450,000 |
€24.5–€45 million |
| Japan |
20–30 |
¥50 million |
¥1–¥1.5 billion |
Total estimated global revenue: approximately $200 million annually.
Risks and Opportunities
Risks
- Market access restrictions may lower utilization.
- Pricing pressures from payers could result in discounts.
- Discoveries of alternative therapies or biosimilars could erode market share.
Opportunities
- New indications or expanded approvals could increase patient population.
- Targeted patient identification may improve utilization.
- Cost reductions in manufacturing could lead to improved margins.
Key Takeaways
- NDC 45802-0953 (Sebelipase alfa) is used to treat rare lipid disorder LAL-D.
- The global market size remains small, with fewer than 1,000 treated patients.
- US prices range around $400,000–$500,000 annually; European and Japanese prices are comparable.
- Revenue estimates for 2023 approximate $200 million globally.
- Pricing is likely stable with slight increases, driven by manufacturing costs and demand growth from expanded indications.
Frequently Asked Questions
1. Will the price of Sebelipase alfa decline with biosimilar entry?
It is unlikely in the short term. Biosimilar development for rare enzyme therapies faces scientific and regulatory challenges, and no biosimilar is currently near approval.
2. How might new indications affect the market?
Additional approved uses or broader labeling could increase patient numbers and revenue. However, regulatory hurdles may delay such expansions.
3. What factors influence reimbursement levels?
Market access negotiations, healthcare system budgets, and payer policies significantly affect pricing and reimbursement.
4. Are there emerging competitors for this drug?
No direct biosimilars exist. Alternative therapies are primarily supportive, and the rarity of LAL-D limits competition.
5. Could manufacturing costs impact future pricing?
Yes. Increased complexity or supply chain disruptions might raise costs, potentially leading to price hikes if approved.
Sources
[1] FDA. (2015). Approval of Sebelipase alfa. Retrieved from https://www.fda.gov
[2] Brighton Therapeutics. (2022). Product information and pricing estimates.
[3] Marketplace reports. (2022). Rare disease enzyme therapies market analysis.
[4] European Medicines Agency. (2022). Product approval data.
[5] GlobalData. (2022). Rare disease market forecasts.
